A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Go Back to All Clinical Trials

A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies

A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Recruitment Status

Contact the research team to learn more about this study.

Recruitment Status

212-263-4432

646-754-7432